Evidence map›Paper›PMID 29721935›Full record

ReviewAdvances in experimental medicine and biology2018

Nanoparticles as Delivery Vehicles for the Treatment of Retinal Degenerative Diseases.

Yuhong Wang, Ammaji Rajala, Raju V S Rajala

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Research Models and Gene Augmentation Therapy forFrontiers in neuroscience · 2020
    Review
  6. Lipid nanoparticles for delivery of messenger RNA to the back of the eye.Journal of controlled release : official journal of the Controlled Release Society · 2019
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yuhong WangDepartment of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Ammaji RajalaDepartment of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Raju V S RajalaDepartment of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. raju-rajala@ouhsc.edu.

Funding

P30-CENTER CORE GRANT FOR VISION RESEARCHP30EY021725 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Michelle C Callegan, MICHAEL H ELLIOTT · 2011 to 2026
$10.5M
SECOND MESSENGERS IN THE RETINAR01EY000871 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI RAJALA, RAJU VS · 1985 to 2020
$7.2M
NEI NIH HHS EY00871NEI NIH HHS P30 EY021725NEI NIH HHS R01 EY000871
6 · The paper itself

Abstract

Over the last few years, huge progress has been made in the understanding of molecular mechanisms underlying the pathogenesis of retinal degenerative diseases. Such knowledge has led to the development of gene therapy approaches to treat these devastating disorders. Non-viral gene delivery has been recognized as a prospective treatment for retinal degenerative diseases. In this review, we will summarize the constituent characteristics and recent applications of three representative nanoparticles (NPs) in ocular therapy.

Indexed as

Gene Transfer TechniquesAnimalscis-trans-IsomerasesGenetic TherapyGenetic VectorsHumansLiposomesMetal NanoparticlesMice, KnockoutNanoparticlesPolyethylene GlycolsPolymersRetinal DegenerationRetinoid Isomerohydrolasecis-trans-IsomerasesLiposomesPolyethylene GlycolsPolymersRetinoid IsomerohydrolaseBlindnessLipid nanoparticlesMetal-based nanoparticlesNanoparticlesNon-viral vectorsOcular diseasesPolymer-based nanoparticlesRetinal degeneration

Identifiers

PMID29721935
PMCPMC6417423

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.